APA (7th ed.) Citation

Findlay, A., Turner, C., Schilter, H., Deodhar, M., Zhou, W., Perryman, L., . . . Jarolimek, W. (2021). An activity‐based bioprobe differentiates a novel small molecule inhibitor from a LOXL2 antibody and provides renewed promise for anti‐fibrotic therapeutic strategies. Clinical & Translational Medicine, 11(11), 1. https://doi.org/10.1002/ctm2.572

Chicago Style (17th ed.) Citation

Findlay, Alison, et al. "An Activity‐based Bioprobe Differentiates a Novel Small Molecule Inhibitor from a LOXL2 Antibody and Provides Renewed Promise for Anti‐fibrotic Therapeutic Strategies." Clinical & Translational Medicine 11, no. 11 (2021): 1. https://doi.org/10.1002/ctm2.572.

MLA (9th ed.) Citation

Findlay, Alison, et al. "An Activity‐based Bioprobe Differentiates a Novel Small Molecule Inhibitor from a LOXL2 Antibody and Provides Renewed Promise for Anti‐fibrotic Therapeutic Strategies." Clinical & Translational Medicine, vol. 11, no. 11, 2021, p. 1, https://doi.org/10.1002/ctm2.572.